In Brief This Week: Danaher; ACGT, CAP; Thermo Fisher; Quest, CDC; Cleveland Clinic Labs, ACL Labs; More | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher said this week that it anticipates its second-quarter diluted net earnings per share to be "slightly above" the high end of its previously announced guidance of between $.80 and $.85. Core revenue growth, it added is expected to also be "slightly above" the previous guidance of between 1 percent and 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.